Sirolimus micro/nano particles coated drug-eluting stents using QbD paradigm: Potential approach for the amelioration of arterial diseases
Sarika A. Jadhav,Ankur J. Raval,Arpit B. Jariwala,Chhaya B. Engineer,Vandana B. Patravale
DOI: https://doi.org/10.1016/j.jddst.2024.105629
IF: 5
2024-04-05
Journal of Drug Delivery Science and Technology
Abstract:Highlights • Explored sirolimus-encapsulated biodegradable polymeric coatings for drug-eluting stents in the treatment of arterial diseases, addressing safety concerns related to non-biodegradable polymers and cytotoxic drugs. • Delivery of safer therapeutic: anti-proliferative cytostatic agent. • The stents were coated differently, with each receiving either micro or nanoparticles separately demonstrate the potential for improved coating mass transfer efficiency, a desired prolonged drug release profile, and minimal coating time, suggesting a promising approach to enhance the treatment of in-stent restenosis (ISR) and arterial diseases. • The study demonstrates the effectiveness and reliability of the Quality by Design approach for coating micro or nanoparticles onto drug-eluting devices, resulting in improved product quality-a first in the field. • Comparative study of process parameters for coating micro and nanoparticles on drug-eluting stents-for the first time in the field. Cytotoxic drugs with non-biodegradable or biodegradable polymeric coated stents induce apoptosis and also lead to complications like local tissue inflammation. This study is aimed at demonstrating the quality by design (QbD) approach in the development of nano- and micro-particles coated drug-eluting stents (DES) encapsulating a cytostatic drug in biodegradable polymer with the potential to produce safe, targeted, and efficient drug delivery for the amelioration of life-threatening arterial diseases. Freeze-dried sirolimus (SRL) encapsulated poly lactic-co-glycolic acid (PLGA) nano- and micro-particles were fabricated by solvent evaporation technique and characterized for various physicochemical parameters like structural and thermal analyses, crystallinity, particle size, morphology, drug entrapment, and drug release rate. QbD relied on three critical process parameters (CPP), including nitrogen pressure, solution flow rate, and distance, while critical quality attributes (CQA) such as coating mass transfer efficiency, coating uniformity, drug elution rate, drug content on the stent, and coating time, were evaluated as dependent variables. The particles were coated on the cobalt-chromium-L605 alloy stent platform. The central composite design followed by multiple linear regression analysis and 3D plots were used for analyzing the impact of the dependent variables on the CPP. FTIR analysis confirmed drug-excipient compatibility. Freeze-dried particles exhibited sizes of 4.53 ± 2.3 μm for Microparticles (MPs) and 158 ± 3.1nm for Nanoparticles (NPs), with high drug entrapment of 96.8 ± 1.08% and 86.21 ± 2.08%, respectively. DSC and XRD analyses supported drug entrapment findings. Furthermore, an initial burst release of SRL 16 ± 2.08% for MPs and 25 ± 3.26% for NPs occurred in the initial 0.5 h, followed by prolonged drug release over 48 h. Design of experiment (DOE) analysis of the CQA indicated optimal coating mass transfer efficiency, improved coating uniformity, and drug elution rate. This study demonstrates the effectiveness of developing drug-loaded biodegradable micro/nano-particles and the reliability of the QbD approach in the use of these particulate systems for coating drug eluting devices - a first in the field. Besides, the study highlights a comparative investigation of process parameters for coating MPs and NPs on DES for the first time in the field. The results from the present study indicate the potential of micro/nanoparticles coated DES to ease the treatment of In-Stent Restenosis (ISR) and arterial diseases. Graphical abstract Download : Download high-res image (203KB) Download : Download full-size image
pharmacology & pharmacy